3D-pharmacophore model for RXR(gamma) agonists.

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Molecular Modeling

Background:

• Retinoid X Receptors (RXRs) are crucial nuclear receptors involved in various physiological processes.
• Selective modulation of RXR subtypes, like RXR(gamma), is a therapeutic target for diverse diseases.
• Developing subtype-selective agonists requires precise molecular understanding.

Purpose of the Study:

• To generate and validate a three-dimensional pharmacophore model for selective retinoid X receptor gamma (RXR(gamma)) agonists.
• To identify key features essential for high-affinity binding and agonist activity at RXR(gamma).
• To provide a tool for the discovery and design of novel, potent RXR(gamma)) agonists.

Main Methods:

• Quantitative structure-activity relationship (QSAR) analysis using the CATALYST HypoRefine program.
• Generation and rigorous validation of multiple pharmacophore models.
• Testing the best model against a diverse set of known RXR(gamma)) agonist and antagonist molecules.

Main Results:

• An optimal pharmacophore model (Hypo-1) was identified, featuring three hydrophobic aliphatic groups (HAL), one hydrophobic aromatic ring (HAR), and one hydrogen bond acceptor (HBA).
• The model incorporated five excluded volumes to define spatial constraints.
• Validation demonstrated high predictive accuracy for agonist activity and the ability to identify potent compounds.

Conclusions:

• The validated 3D pharmacophore model serves as a reliable tool for virtual screening and drug design.
• This model facilitates the discovery of novel and selective RXR(gamma)) agonists with improved therapeutic potential.
• The findings contribute to the rational design of compounds targeting RXR(gamma) for various applications.